Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/25/24
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial ResultsGlobeNewsWire • 07/18/24
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EUGlobeNewsWire • 06/28/24
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?Zacks Investment Research • 06/06/24
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/05/24
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA CongressGlobeNewsWire • 05/24/24
Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/07/24
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/07/24
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare ConferenceGlobeNewsWire • 05/06/24
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingGlobeNewsWire • 05/01/24
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)GlobeNewsWire • 04/26/24
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial ResultsGlobeNewsWire • 04/23/24
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/01/24
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina AdvisorGlobeNewsWire • 03/11/24
Apellis Pharmaceuticals, Inc. (APLS) Q4 and Full Year 2023 Earnings Call TranscriptSeeking Alpha • 02/27/24
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/27/24